to vice president of financing and administration...Pepscan Therapeutics, of Lelystad, the Netherlands, named Peter Timmerman chief technology officer and appointed Klaus Schwamborn chief development officer

VaxInnate Corp., of Cranbury, N.J., named Thomas Hofstaetter president and CEO, and Alan Shaw, who previously held that position, has assumed the newly created role of chief scientific officer and becomes board chairman

Cephalon Inc., of Frazer, Pa., promoted Kevin Buchi to chief operating officer, Wilco Groenhuysen to executive vice president and chief financial officer and Alain Aragues to executive vice president of Cephalon Europe

Tom Amick will serve as president and CEO, while Edward L. Field was named executive vice president and chief business officer...Banyan Biomarkers Inc., of Alachua, Fla., appointed Jackson Streeter CEO and chief medical officer

Diffusion Pharmaceuticals LLC, of Charlottesville, Va., named David R. Jones chief medical officer and member of its scientific advisory board...GeoVax Labs Inc., of Atlanta, appointed Mark J. Newman vice president of research and development...ImmuCell Corp., of Portland, Maine, added Bobbi Jo Kunde as director of sales and marketing

BIND Biosciences Inc., of Cambridge, Mass., appointed Scott Minick president and CEO...Cel-Sci Corp., of Vienna, Va., appointed Todd S. Burkhart vice president of manufacturing/facilities and commercial operations...CrystalGenomics Inc., of Seoul, South Korea, and CG Pharmaceuticals Inc., of Emeryville, Calif., appointed Eric M. Nelson vice president of business development

Senesco Technologies Inc., of New Brunswick, N.J., appointed Jack Van Hulst president and CEO...Siriuis Genomics, of Vancouver, British Columbia, appointed Chris Wagner president and CEO...UCB SA, of Brussels, Belgium, named Ismail Kola executive vice president of UCB and president of UCB New Medicines

Anesiva Inc., of South San Francisco, named Ted W. Love and David C. U'Prichard to its board, following completion of the merger with Arcion Therapeutics...CellCyte Genetics Corp., of Eastgate, Wash., appointed Douglas Cerretti chief science officer and director of business development...It also appointed Andrew K. W. Powell executive vice president, general counsel and secretary

RetroVirox Inc., of San Diego, appointed Ronald C. Griffith vice president of research and development...Seaside Therapeutics LLC, of Cambridge, Mass., appointed Daniel E. Geffken chief operating officer, John C. Amedio vice president of manufacturing and process development and W. Roger Rush vice president of preclinical development...XOMA Ltd., of Berkeley, Calif., appointed Susan Kramer vice president, project and alliance management

Apthera Inc., of Scottsdale, Ariz., appointed Ira Z. Leiderman executive chairman and named Mary Ann Gray to the board...Dendreon Corp., of Seattle, elected Ian Clark and Pedro Granadillo to its board...NeoStem Inc., of New York, named Teresa Lepore vice president, sales and marketing

Ocular Therapeutix Inc., of Waltham, Mass., named Daniel Myers and Bernard Haffey to its board...Sigma-Aldrich, of St. Louis, appointed George M. Church a director and named George Miller senior vice president, general counsel and secretary

Micromet Inc., of Bethesda, Md., appointed Jan Fagerberg senior vice president and chief medical officer...MorphoSys AG, of Martinsried, Germany, appointed Lisa Rojkjaer vice president and head of clinical development...and promoted David Dodds to president of Sucampo Pharma Europe Ltd

BioMicro Systems, of Salt Lake City, appointed Rob Parry president and chief operating officer...Ironwood Pharmaceuticals Inc., of Cambridge, Mass., named Thomas McCourt chief commercial officer and senior vice president of marketing and sales, and appointed David Ebersman to its board

Spherix Inc., of Bethesda, Md., named Ram R. Nimmagudda director of new business development. Tethys Bioscience Inc., of Emeryville, Calif., promoted Michael Richey to president. Trinity Biosystems, of Menlo Park, Calif., appointed René Castro chief business officer. Vantia Therapeutics, of Southampton, UK, appointed Andrew Crockett vice president of business development. Vivalis, of Nantes, France, appointed Philippe Rousseau chief financial officer.

AAIPharma Services Corp., of Wilmington, N.C., appointed Christopher Smith vice president of quality and regulatory affairs...Bioheart Inc., of Sunrise, Fla., named Karl E. Groth chairman of the board, Peggy A. Farley chief operating officer and Mark P. Borman chief financial officer...PharmAthene Inc., of Annapolis, Md., appointed Charles A. Reinhart III senior vice president and chief financial officer

Immucor Inc., of Norcross, Ga., named Geoffrey S. Crouse vice president and chief operating officer...Third Rock Ventures LLC, of Boston, appointed Philip R. Reilly and Gregory L. Verdine venture partners, and Craig M. Greaves recruiting partner

Novavax Inc., of Rockville, Md., appointed John J. Trizzino senior vice president of international and government alliances

senior vice president of corporate strategy and chief financial officer...vice president of finance and chief financial officer...Novavax Inc., of Rockville, Md., appointed Frederick W. Driscoll vice president, chief financial officer and treasurer

EGEN Inc., of Huntsville, Ala., promoted Jason Fewell to vice president of preclinical research and development...Nuon Therapeutics Inc., of San Mateo, Calif., appointed Paulette Dillon chief business officer and Tito Serafini chief scientific officer...Xanodyne Pharmaceuticals Inc., of Newport, Ken, appointed Natasha Giordano as chief commercial officer, Rita O'Connor as chief financial & information officer, and Peter Wentworth as senior vice president for human resources